Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Reports Concordance Data from MDS Concept Study
JERSEY, Channel Islands , Dec. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray
View HTML
Toggle Summary Quotient Limited to Participate in the Jefferies 2019 London Healthcare Conference
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt , the Company’s President of R&D and Manufacturing, Ed Farrell , and the Company’s Chief
View HTML
Toggle Summary Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per
View HTML
Toggle Summary Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the
View HTML
Toggle Summary Quotient Limited Provides Positive Updates on MosaiQ’s Initial Serological Disease Screening and Expanded Immunohematology Microarrays, on Hypercare Launch and on a Successful Facility Audit and Reports Second Quarter Fiscal 2020 Financial Results
Positive results from the initial Serological Disease Screening microarray US field trial Positive Verification and Validation data for expanded Immunohematology microarray An additional three Hypercare launch sites initiated in 2019 Successful ISO 13485 : 2016 audit of MosaiQ microarray
View HTML
Toggle Summary Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
JERSEY, Channel Islands , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results.
View HTML
Toggle Summary Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call
JERSEY, Channel Islands , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019.
View HTML
Toggle Summary Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter
Successful Extended Immunohematology Verification and Validation data  paving the way for field trials Positive customer feedback and three additional hypercare sites initiated Preliminary quarterly revenue higher than guided JERSEY, Channel Islands , Oct.
View HTML
Toggle Summary Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results
First European hypercare launch site initiated following CE mark approval Initial Serological Disease Screening microarray submitted for CE marking U.S. field trial activities for initial Serological Disease Screening commenced 13 blood grouping reagents approved by the FDA for use with OEM
View HTML